CRP and rheumatoid arthritis: In addition, considering the report that the disease activity evaluated based on the Disease Activity Score in 28 joints CRP (DAS28-CRP) improved continuously from four weeks to 12 weeks in patients with RA [14], we regard the change in CRP in this trial as an indicator of a lack of response to filgotinib.